Product Presentations

In 2002, manufacturing innovations led to the introduction of a thimerosal-free influenza vaccine. Since 1985, more than 42 million doses of influenza vaccine have been distributed globally. This includes approximately 19.2 million doses of CSL Biotherapies’ thimerosal-free formulation, distributed since its first market introduction.

Afluria^® Influenza Virus Vaccine – a new flu vaccine from a reliable source.

The Word Is Out. Pass It On.

Protect your patients and yourself

Recommend immunization against influenza to all appropriate patients.

Available in 2 convenient, latex-free formulations:

Afluria Single-use Prefilled Syringe

Afluria^® Single-use, Prefilled Syringe (0.5 mL)
Thimerosal-free
NDC 33332-007-01
CPT code 90656

Afluria Multi-dose Vial

Afluria^® 5 mL Multi-dose Vial (contains ten 0.5 mL doses/vial)
NDC 33332-107-10
CPT code 90658

Store refrigerated at 2-8°C (36-46°F). Do not freeze. Protect from light. Do not use Afluria^® beyond the expiration date printed on the label.

Important Safety Information

Afluria^® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria^®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria^®.

Afluria^® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria^®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria^® may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria^® should be based on careful consideration of the potential benefits and risks.

Click here for full PRESCRIBING INFORMATION.